Boston Scientific: Pipeline Will Aid Return To Growth By Year End
This article was originally published in The Gray Sheet
Potential growth drivers identified by the firm during its April 19 first-quarter earnings call include the Ingenio family of pacemakers and BSX-manufactured Promus Element everolimus-eluting stent system.
You may also be interested in...
Johnson & Johnson’s mid-year Synthes purchase drives third-quarter revenue growth. Abbott spin-off on track. More news briefs.
Recent product approvals and launches include St. Jude’s Assura and Ellipse ICDs, Boston Scientific’s Ingenio pacemakers and Medtronic’s Valiant Captivia thoracic stent graft system.
The latest product approvals and launches in cardiology, ophthalmology and more.